Cargando…
Experimental evidence and network pharmacology-based analysis reveal the molecular mechanism of Tongxinluo capsule administered in coronary heart diseases
Background: Tongxinluo (TXL) capsule, a polypharmacy derived from traditional Chinese medicine (TCM), has been widely used in coronary heart disease (CHD), while the underlying mechanism of TXL capsule is still unclear. The present study aimed at investigating the underlying mechanism of TXL acting...
Autores principales: | Li, Guode, Xu, Qingbo, Han, Kedong, Yan, Wenhe, Huang, Chaopei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560518/ https://www.ncbi.nlm.nih.gov/pubmed/32990315 http://dx.doi.org/10.1042/BSR20201349 |
Ejemplares similares
-
Andrographolide in atherosclerosis: integrating network pharmacology and in vitro pharmacological evaluation
por: Shi, Shuai, et al.
Publicado: (2022) -
An updated meta-analysis showed smoking modify the association of GSTM1 null genotype on the risk of coronary heart disease
por: Song, Yadong, et al.
Publicado: (2021) -
Novel pharmacological approaches in abdominal aortic aneurysm
por: Puertas-Umbert, Lídia, et al.
Publicado: (2023) -
Gut microbiota in coronary artery disease: a friend or foe?
por: Zhang, Bo, et al.
Publicado: (2020) -
The roles of ANRIL polymorphisms in coronary artery disease: a meta-analysis
por: Hu, Lina, et al.
Publicado: (2019)